MedPath

Juvenile Bipolar Disorder Outpatient Program

Phase 4
Conditions
Bipolar Disorder
Attention Deficit Disorder With Hyperactivity
Interventions
Drug: Psychopharmacotherapy
Registration Number
NCT01000402
Lead Sponsor
Federal University of Rio Grande do Sul
Brief Summary

This is an outpatient program for children and adolescents with bipolar disorders. The naturalistic approach of the program will allow a proper investigation of the disorder, assessment of environmental and biological factors, the conduction of treatment studies, and follow-up of the subjects.

Detailed Description

Inclusion criteria:

Age 6-17 years old, male and female. Bipolar Disorder I, II, and NOS (subjects presenting episodes of distinct abnormally and persistently elevated, expansive, or irritable mood, accompanied by at least three -or four if the mood is only irritable - Criteria B symptoms and present to a significant degree for at least 24 hours.

Severe Mood Dysregulation (SMD), as defined by Brotman et al. (American Journal of Psychiatry, 2007)

Exclusion criteria:

Presence of a diagnosis of Pervasive Developmental Disorder, Schizophrenia, Drug Use Disorder, and any other counter indications to outpatient treatment (significant suicide or homicide risk)

Diagnosis:

K-SADS-PL-W WASI Clinical Interview

Outcome Measures:

CBCL for general psychopathology YMRS, CMRS-P, CMRS-T for manic symptoms CDRS and CDI for depressive symptoms SNAP-IV for ADHD symptoms Scared-C and Scared-P for anxiety symptoms CGI for clinical impression, CGAS for global functioning Petersen Pubertal Scale Mood Symptom Questionnaire for SMD Screening tests for leaning disorders Family Environmental Scale, Life Events Scale, Expressed Emotion Adjective Checklist, Resilience Scale, Quality of Life for environmental and psychological factors Medication Adverse Events Checklist

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
150
Inclusion Criteria
  • 6-18 years-old;
  • Bipolar Disorder I, II or NOS
  • Severe Mood Dysregulation
Exclusion Criteria
  • Schizophrenia
  • Pervasive Developmental Disorder
  • Drug use disorder
  • Severe suicidal or homicidal risk, counterindicating outpatient treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PsychopharmacotherapyPsychopharmacotherapyNo specific arms; Treatment decision based on available guidelines
Primary Outcome Measures
NameTimeMethod
Changes in manic and depressive symptoms over time using YMRS, CMRS-P, CDRS, and CDINaturalistic Study - 2-year follow-up
Polymorphisms at candidate genes for Bipolar Disorder and Attention-Deficit/Hyperactivity DisorderNaturalistic 2-year follow-up
Secondary Outcome Measures
NameTimeMethod
Changes in ADHD symptoms according to SNAP-IVNaturalistic 2-year follow-up
Changes in Anxiety symptoms according to the SCARED-C and SCARED-PNaturalistic 2-year follow-up
Changes in family functioning according to the FES-R, individual functioning according to the EEAC and Resilience Scale, environmental factors according to the Stressful Life Events ScaleNaturalistic 2-year follow-up
Presence and onset of adverse events secondary to treatmentNaturalistic 2-year follow-up
Changes in SMD symptoms according to the Mood Symptom QuestionnaireNaturalistic 2-year follow-up
Changes in general functioning according to the CGI and the CGASNaturalistic 2-year follow-up

Trial Locations

Locations (1)

Hospital de Clinicas de Porto Alegre

🇧🇷

Porto Alegre, RS, Brazil

© Copyright 2025. All Rights Reserved by MedPath